Vaishali Pharma Limited (VAISHALI.NS)
INR 19.0
(0.42%)
INR 19.0
(0.42%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 3.82 Million | 10.79 Million | 13.18 Million | 20.11 Million | 32.18 Million | 28.48 Million |
| Net Income | 7.18 Million | 88.45 Million | 57.28 Million | 14.04 Million | 791.05 Thousand | 11.32 Million |
| Depreciation & Amortization | 5.08 Million | 5.04 Million | 4.56 Million | 4.26 Million | 4.38 Million | 2.68 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | -36.95 Million | -73.61 Million | -51.52 Million | -27.77 Million | -19.14 Million | 1.52 Million |
| Other non-cash items | 69.86 Million | -9.08 Million | 2.86 Million | 29.57 Million | 46.15 Million | 12.93 Million |
| Investing Cash Flow | -1.11 Million | 2.82 Million | -8.46 Million | -1.1 Million | -193.2 Thousand | 8.42 Million |
| Investments in PPE | -1.11 Million | -2.97 Million | -8.64 Million | -1.26 Million | -526.04 Thousand | -2.96 Million |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | 13.13 Million | 5.79 Million | 180.21 Thousand | 156.89 Thousand | 332.83 Thousand | 11.39 Million |
| Financing Cash Flow | 3.22 Million | -17.32 Million | 4.17 Million | -18.11 Million | -31.38 Million | -39.92 Million |
| Debt repayment | -10.53 Million | -45.04 Million | -31.88 Million | -9.37 Million | -4.39 Million | -13.18 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | -1.04 Million | - | - | - |
| Common Stock Issuance | 15.67 Million | 50.31 Million | -1.04 Million | - | - | - |
| Other Financing Activities | 1.05 Million | -22.59 Million | 68.97 Million | -8.74 Million | -26.99 Million | -26.73 Million |
| Accounts receivables | 561 Thousand | 48.95 Million | 82.25 Million | -215.22 Million | -10.44 Million | -48.41 Million |
| Accounts payables | -58.46 Million | -102.86 Million | -121.08 Million | 170.54 Million | -27.94 Million | 18.06 Million |
| Inventory | 26.7 Million | -24.21 Million | -407.46 Thousand | 2.91 Million | 1.01 Million | 8.86 Million |
| Other working capital | -5.76 Million | 4.5 Million | -12.28 Million | 13.97 Million | 18.23 Million | 23.01 Million |
| Cash at beginning of period | 9.84 Million | 13.55 Million | 4.65 Million | 3.76 Million | 3.16 Million | 2.8 Million |
| Cash at end of period | 15.78 Million | 9.84 Million | 13.55 Million | 4.65 Million | 3.76 Million | 3.16 Million |
| Capital Expenditure | -1.11 Million | -2.97 Million | -8.64 Million | -1.26 Million | -526.04 Thousand | -2.96 Million |
| Effect of forex changes on cash | - | - | 445.00 | - | - | 3.37 Million |
| Net cash flow / Change in cash | 5.93 Million | -3.7 Million | 8.89 Million | 891.79 Thousand | 605.59 Thousand | 359.21 Thousand |
| Free Cash Flow | 2.71 Million | 7.82 Million | 4.53 Million | 18.85 Million | 31.66 Million | 25.51 Million |
| Breakdown | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 FY |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -46.82 Million | 7.18 Million | 21.11 Million | 17.03 Million | 15.85 Million | 88.45 Million |
| Depreciation & Amortization | - | 5.08 Million | 1.24 Million | 2.43 Million | 1.19 Million | 5.04 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | - | -36.95 Million | - | 10.76 Million | - | -73.61 Million |
| Other non-cash items | 46.82 Million | 69.86 Million | -21.11 Million | -17.03 Million | -15.85 Million | -9.08 Million |
| Investing Cash Flow | - | -1.11 Million | - | -561 Thousand | - | 2.82 Million |
| Investments in PPE | - | -1.11 Million | - | -679 Thousand | - | -2.97 Million |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | 13.13 Million | - | 118 Thousand | - | 5.79 Million |
| Financing Cash Flow | - | 3.22 Million | - | -1.37 Million | - | -17.32 Million |
| Debt repayment | - | -10.53 Million | - | - | - | -45.04 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | 15.67 Million | - | - | - | 50.31 Million |
| Other Financing Activities | - | 1.05 Million | - | -1.37 Million | - | -22.59 Million |
| Accounts receivables | - | 561 Thousand | - | -9.96 Million | - | 48.95 Million |
| Accounts payables | - | -58.46 Million | - | - | - | -102.86 Million |
| Inventory | - | 26.7 Million | - | 20.72 Million | - | -24.21 Million |
| Other working capital | - | -5.76 Million | - | - | - | 4.5 Million |
| Cash at beginning of period | - | 9.84 Million | 4.26 Million | - | 9.84 Million | 13.55 Million |
| Cash at end of period | - | 15.78 Million | 6.74 Million | 4.26 Million | 12.24 Million | 9.84 Million |
| Capital Expenditure | - | -1.11 Million | - | -679 Thousand | - | -2.97 Million |
| Effect of forex changes on cash | - | - | - | 9.84 Million | - | - |
| Net cash flow / Change in cash | - | 5.93 Million | 2.48 Million | 4.26 Million | 2.39 Million | -3.7 Million |
| Free Cash Flow | - | 2.71 Million | 2.48 Million | -4.33 Million | 2.39 Million | 7.82 Million |
4303
AEGOF
ASIANENE
3303
RITES
CBWBF